Physician profile
Oluseyi Princewill
NPI 1770719288
$1,412.03
in general payments reported to CMS, 2019-2025
18 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $86.16 · 2021: $289 · 2022: $189 · 2023: $366 · 2024: $121 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $215.86 | 2020-2024 | Camzyos |
| Amgen INC. | $194.77 | 2019-2024 | Repatha |
| Medtronic, INC. | $175.85 | 2025 | Symplicity G3 |
| Amarin Pharma, INC. | $121.66 | 2020-2021 | |
| Boston Scientific Corporation | $121.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $113.20 | 2019-2024 | |
| Esperion Therapeutics, INC. | $79.81 | 2020-2021 | |
| Novo Nordisk INC | $70.41 | 2022-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $56.39 | 2021-2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $55.94 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.69 | 2019-2021 | |
| Pfizer INC. | $33.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $24.90 | 2022 | |
| Irhythm Technologies, INC. | $19.97 | 2024 | Zio Xt Patch, Zio Monitor |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $19.67 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $18.41 | 2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oluseyi Princewill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.